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Plenary paper

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate
dehydrogenase–deficient children receiving dapsone
*Allan Pamba,1 *Naomi D. Richardson,2 Nick Carter,3 Stephan Duparc,4 Zul Premji,5 Alfred B. Tiono,6 and Lucio Luzzatto7
1GlaxoSmithKline,

Brentford, United Kingdom; 2Magenta Communications Ltd, Abingdon, United Kingdom; 3GlaxoSmithKline, Stockley Park West, United
Kingdom; 4Medicines for Malaria Venture, Geneva, Switzerland; 5Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; 6Centre National
de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso; and 7Istituto Toscano Tumori (ITT), Florence, Italy

Drug-induced acute hemolytic anemia led
to the discovery of G6PD deficiency. However, most clinical data are from isolated
case reports. In 2 clinical trials of antimalarial preparations containing dapsone
(4,4'-diaminodiphenylsulfone; 2.5 mg/kg
once daily for 3 days), 95 G6PD-deficient
hemizygous boys, 24 G6PD-deficient
homozygous girls, and 200 girls heterozygous for G6PD deficiency received this
agent. In the first 2 groups, there was
a maximum decrease in hemoglobin
averaging -2.64 g/dL (range -6.70 to

+0.30 g/dL), which was significantly
greater than for the comparator group
receiving artemether-lumefantrine (adjusted difference -1.46 g/dL; 95% confidence interval -1.76, -1.15). Hemoglobin
concentrations were decreased by > 40%
versus pretreatment in 24/119 (20.2%) of
the G6PD-deficient children; 13/119 (10.9%)
required blood transfusion. In the
heterozygous girls, the mean maximum
decrease in hemoglobin was -1.83 g/dL
(range +0.90 to -5.20 g/dL); 1 in 200 (0.5%)
required blood transfusion. All children even-

tually recovered. All the G6PD-deficient children had the G6PD A- variant, ie, mutations
V68M and N126D. Drug-induced acute hemolytic anemia in G6PD A- subjects can be
life-threatening, depending on the nature
and dosage of the drug trigger. Therefore,
contrary to current perception, in clinical
terms the A- type of G6PD deficiency cannot be regarded as mild. This study is registered at http://www.clinicaltrials.gov as
NCT00344006 and NCT00371735. (Blood.
2012;120(20):4123-4133)

Introduction
Glucose 6-phosphate dehydrogenase (G6PD) deficiency is common in populations that have been exposed to malaria, either in the
present or in the past.1-4 This association appears to have arisen
through natural selection,5 as G6PD-deficient individuals are
relatively protected from severe malaria.6-8 This is particularly
important in children because most fatalities from malaria (� 85%)
occur in patients younger than 5 years of age. Malaria has been a
powerful selective force in endemic areas for several thousands
of years. Thus, it is perhaps not surprising that an estimated
330 million people worldwide are G6PD deficient.4
G6PD catalyzes the first step in the pentose phosphate pathway,
oxidizing glucose 6-phosphate to 6-phosphogluconolactone, coupled
to the reduction of nicotinamide adenine dinucleotide phosphate
(NADP) to NADPH. In the erythrocyte, a cell with limited
metabolic resources, this is the rate-limiting step in the production
of NADPH, a key redox metabolite. In steady-state conditions,
NADPH produced in G6PD-deficient erythrocytes by residual
G6PD activity is adequate. However, G6PD-deficient erythrocytes
are uniquely sensitive to any extra oxidative stress: this will cause
cellular damage and premature destruction of erythrocytes through
both intravascular and extravascular hemolysis.9 Clinically, this
manifests as acute hemolytic anemia (AHA) with malaise, weakness, and abdominal or lumbar pain, which may be associated with
passing dark urine (hemoglobinuria), followed by jaundice.9
The best characterized exogenous triggers of hemolysis in
G6PD-deficient subjects are, apart from infection, fava beans and

drugs.10 The clinical course of primaquine-induced hemolysis
(which eventually led to the discovery of G6PD deficiency11) was
charted in detail more than half a century ago in 6 adult
volunteers.12 Since then, numerous drugs have been implicated as
causes of G6PD-related hemolysis, most notably dapsone and other
sulfones, methylthioninium chloride, niridazole, nitrofurantoin,
pamaquin, quinolones, rasburicase, and sulfonamides,13 although
most reports are of isolated cases.14
By the year 2000, the spread of chloroquine-resistant Plasmodium falciparum had made the malaria situation even worse than
before in many African countries.15 The development of a combination of chlorproguanil-dapsone, initiated in the 1990s, was accelerated as a response to this situation.16 A randomized trial of
chlorproguanil-dapsone against sulfadoxine-pyrimethamine led to
the combination receiving a license in 2003 under the name
Lapdap. A greater number of hematologic adverse events occurred
in the dapsone-containing arm versus the comparator.17,18 However, the relative risk to G6PD-deficient versus G6PD-normal
patients remained not exactly defined because G6PD genotyping
was performed in some patients, but not prospectively.17-19 The
safety risks of dapsone were outlined at a World Health Organization (WHO) Technical Consultation; G6PD testing was recommended before treatment and a hemoglobin level of < 7.0 g/dL
was set as a contraindication for its use in any patient.18
The WHO technical consultation noted that data addressing
specifically the risk of G6PD-related AHA in patients with malaria
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receiving dapsone were not available.18 Anemia had only been
occasionally documented with a combination of pyrimethamine
and dapsone that was introduced in 1953 (Maloprim) and used
mostly for prophylaxis.20 Extensive use of dapsone in leprosy was
generally at low doses and under conditions in which drug adverse
event reporting would not be expected to occur. On the other hand,
data from a study in adult healthy male volunteers had indicated
that dapsone did decrease hemoglobin concentrations to a greater
degree in primaquine-sensitive (ie, G6PD-deficient) individuals
(n = 5) than in G6PD-normal control subjects (n = 10).21
In consideration of these issues, the protocol for 2 large phase
3 trials of the triple combination chlorproguanil-dapsoneartesunate (CDA) required G6PD genotyping of all patients and
frequent blood monitoring.22,23 These studies, conducted at multiple sites in Africa, included 1806 malaria patients exposed to
dapsone (2.5 mg/kg once daily for 3 days); the majority (95.0%)
were children younger than 15 years of age.22,23 G6PD A- was the
only mutation detected.24 The data obtained in these trials determined categorically that the use of CDA created an unacceptable
risk of hemolysis in G6PD-deficient patients with malaria.22,23
CDA development was discontinued and Lapdap voluntarily
withdrawn.19,22,23
In these CDA phase 3 trials, the risk of AHA was evaluated with
the use of a composite “hemoglobin safety” end point, defined
prospectively as a hemoglobin decrease of > 4.0 g/dL or > 40%
versus pretreatment, or hemoglobin < 5.0 g/dL, or blood transfusion.22,23 When this composite end point was used, there was a
significant difference between G6PD-normal and G6PD-deficient
patients but not between G6PD-normal patients and female patients
heterozygous for G6PD deficiency. This picture was clearly not the
whole one because some heterozygous female patients had severe
hemolysis.22,23
Here, we are reporting in full on the clinical course of acute
hemolytic events in 119 children (< 15 years) treated with dapsone
(either as chlorproguanil-dapsone or as CDA) in phase 3 trials who
were hemizygous or homozygous for G6PD A-. This series is the
largest ever reported of the hematologic impact of any drug on
G6PD-deficient subjects. Most studies of drug-induced AHA are
retrospective in the sense that investigations were initiated only
after the patient had become ill. In contrast, this report is compiled
from data collected prospectively in which a standard protocol was
used. This allows us to examine the onset and time course and the
full spectrum of hematologic effects of dapsone-induced AHA. The
large dataset also allows statistical analyses that were not possible
within the individual studies. The analysis of the 200 G6PD
heterozygous females who received dapsone is unique in terms of
pharmacogenetics because these individuals cannot be reliably
identified by routine G6PD deficiency testing, only by appropriate
genotyping. Overall, our findings indicate that contrary to a
widespread perception, in many subjects with the African type of
G6PD deficiency (G6PD A-), AHA is not mild and can be
life-threatening.

Methods
Study design
Data were obtained from 2 multicenter, randomized, double-blind, clinical
trials of CDA in acute P falciparum malaria. Details of the conduct of the
2 studies are included in 2 previous articles.22,23 To summarize, patients
were randomized 2:1 CDA versus the comparator. In study 006,23 both
treatment arms contained dapsone, administered as CDA or as

chlorproguanil-dapsone to patients ages > 1 year enrolled from centers in
Ouagadougou, Burkina Faso; Kumasi, Ghana; Doneguebougou and Banambani, Mali; and Ile-Ife, Jos and Lagos, Nigeria, between April 2006 and
May 2007. In study 005,22 CDA was compared with artemetherlumefantrine (AL) in patients ages > 1 to < 14 years enrolled from centers
in Bobo-Dioulasso, Burkina Faso; Kintampo, Ghana; Eldoret, Kilifi, and
Pingilikani, Kenya; Ibadan, Enugu, Jos, and Calabar, Nigeria; and Bagamoyo and Kiwangwa, Tanzania, between June 2006 and August 2007.
Investigators were blind to drug treatment and G6PD genotype and
phenotype.
Ethics statement
Both clinical trials were conducted according to Good Clinical Practices,
applicable regulatory requirements, and the Declaration of Helsinki. Ethical
approval was obtained from the participating center’s ethics committee or
institutional review board and the WHO Special Program for Research and
Training in Tropical Diseases. Parents or guardians of all patients provided
written or oral witnessed informed consent; when patients were 12 years or
older, their own assent was required as well.
Participants
Eligible subjects were of either sex presenting with microscopically
verified acute uncomplicated P falciparum malaria (parasite count
2000-200 000 f-LL-1), fever within the previous 24 hours, hemoglobin
> 7.0 g/dL or hematocrit > 25%, and weight > 7.5 kg. Exclusion criteria
are detailed in the previously published articles.22,23
Procedures
During screening, a full medical history was obtained and a clinical
examination performed. Asexual parasite counts were determined via the
use of WHO methods.22,23,25 Eligible patients received CDA 2/2.5/4 mg/kg
or chlorproguanil-dapsone 2/2.5 mg/kg (both GlaxoSmithKline), both
given once daily for 3 days (days 0, 1, 2), or 6-dose AL (Novartis Pharma
AG), also given over the course of 3 days.22,23 Patients remained hospitalized between days 0 and 3 in study 005. In study 006, treatment was
ambulatory from days 0 to 3; patients were subsequently visited at home
from days 4 to 6 for early detection of clinical abnormalities. Follow-up was
until day 42 in study 005 and day 28 in study 006. Venous blood samples
(2 mL) for hematology evaluations were taken at pretreatment (day 0); days
1, 2, 3, 7, 14, and 28 in both studies; and at day 42 in study 005. Clinical
chemistry assessments were made in study 005 at pretreatment (day 0);
days 3, 7, and 42 plus days 14 and 28 if previous results were abnormal; and
in study 006 at pretreatment, days 3, 7, and 28 plus day 14 if previous
results were abnormal.
G6PD genotyping
G6PD genotyping was performed at the Kenya Medical Research Institute,
Nairobi, Kenya, with quality control conducted at the Shoklo Malaria
Research Unit, Mae Sot, Thailand. PCR amplification was used on a section
of the G6PD gene, including G6PD B (wild type), G6PD A (A376G), and
G6PD A- (G202A, A542T, G680T, and T968C). The analytical methods
have been reported previously.24
Outcomes and statistical methods
The analysis included all enrolled patients ages < 15 years with the G6PD
genotype available and hemoglobin data at pretreatment, day 3, and day 7.
Data for patients who received dapsone within the CDA or chlorproguanildapsone combination were pooled (referred to henceforth as the dapsone
group) and compared with results from the AL treatment arm. Patient
pretreatment data were reported by the use of descriptive statistics. Changes
from pretreatment for hemoglobin and hematocrit were defined as the
difference between the pretreatment value and the lowest posttreatment
value (maximum decrease or minimum increase), referred to as the
“maximum decrease.” For other parameters, changes from pretreatment
were defined as the difference between the pretreatment value and the
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Table 1. Pretreatment clinical and laboratory data

Parameter

G6PD-normal
males
(n = 806)

Hemizygous G6PDdeficient males (n =
122)

G6PD-normal
females
(n = 636)

Heterozygous
females
(n = 236)

Homozygous G6PDdeficient females (n =
30)

All subjects
(n = 1830)

Age, y
Temperature, °C

4.4 ± 3.1
37.88 ± 0.99

4.3 ± 3.2
37.75 ± 0.94

4.6 ± 3.2
37.90 ± 0.96

4.2 ± 3.1
37.81 ± 0.96

3.9 ± 3.1
38.05 ± 0.91

4.4 ± 3.1
37.87 ± 0.97

Parasitemia, f-LL-1

52 516 (216-323 361)

65 220 (1626-705 600)

56 722 (185-389 415)

53 429 (484-303 400)

48 452 (1026-211 546)

54 876 (185-705 600)

Hemoglobin, g/dL

10.00 ± 1.57

9.94 ± 1.59

10.19 ± 1.56

9.94 ± 1.36

9.47 ± 1.64

10.05 ± 1.55

Hematocrit, %

30.5 ± 4.3

30.2 ± 4.6

31.0 ± 4.4

30.2 ± 3.8

29.0 ± 4.1

30.6 ± 4.3

Reticulocytes, %

1.4 ± 1.6

1.5 ± 1.4

1.5 ± 1.9

1.4 ± 1.2

1.7 ± 1.4

1.5 ± 1.7

WBC X109/L

9.6 ± 4.0

9.8 ± 4.3

9.6 ± 4.0

9.7 ± 3.8

9.0 ± 4.3

9.6 ± 4.0

Unconj bil, f-Lmol/L

10.1 ± 11.1

11.5 ± 13.1

10.8 ± 10.5

12.3 ± 19.1

11.3 ± 8.8

10.7 ± 12.4

Platelets X 109/L

197.0 ± 109.3

195.6 ± 88.9

199.3 ± 119.8

189.4 ± 98.6

216.4 ± 134.1

197.0 ± 111.0

ALT, IU/L

26.1 ± 20.7

33.8 ± 82.7

31.8 ± 42.1

29.0 ± 32.2

26.2 ± 18.1

29.0 ± 37.6

AST, IU/L

44.7 ± 32.3

52.4 ± 80.5

47.6 ± 44.6

43.8 ± 33.3

44.0 ± 23.8

46.1 ± 41.8

Dapsone group, n

631

95

514

200

24

1464

AL group, n

175

27

122

36

6

366

AL indicates artemether-lumefantrine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Unconj bil, unconjugated bilirubin; and WBC, white blood cell.
All baseline and laboratory values are mean ± SD except for parasitemia which is mean (range).

highest posttreatment value (maximum increase or minimum decrease),
referred to as the “maximum increase.”
All statistical analyses were performed posthoc. Differences between
populations were compared with ANOVA, where adjustments were made
for sex, center, age, weight, pretreatment hemoglobin, and G6PD status and
in the case of the dapsone group also for study (005 or 006).

Results
Patients

Of 1830 patients with acute uncomplicated malaria, 928 were male
and 902 female (Table 1). Of the males, 13.1% (122/928) were
G6PD deficient. Among females, 26.2% (236/902) were heterozygous for G6PD deficiency (henceforth referred to as heterozygotes), and 3.3% (30/902) were homozygous for G6PD deficiency
(henceforth referred to as homozygotes). On the basis of the
frequency of the A- gene in male patients, these figures demonstrated no significant deviation from the Hardy-Weinberg equilibrium. Dapsone was received by 119 G6PD-deficient children
(95 were hemizygotes and 24 homozygotes) as well as by
200 heterozygotes.
At the time they entered the study, most subjects were moderately anemic, probably resulting, at least in part, from their acute
malaria (Table 1). Other pretreatment parameters were within normal
limits, except for an elevated serum bilirubin, which commonly is
observed in patients with acute malaria.26 There were no relevant
differences in the mean values or the distributions of pretreatment
parameters according to G6PD genotype (Table 1). There were no
important differences in the pretreatment parameters of the dapsone group compared with the AL group (data not shown).
Clinical course in comparator group

Patients receiving AL had a small mean decrease in hemoglobin
concentration of -0.65 g/dL on day 1 (see supplemental Figure 1,
available on the Blood Web site; see the Supplemental Materials
link at the top of the online article). From day 2 onward,
hemoglobin levels stabilized and then increased in the majority of
patients (Figure 1). Statistical analyses showed that there was no
effect of G6PD status on hematologic parameters that might
suggest AHA in the AL group (Table 2). In principle, we can think
of 2 not mutually exclusive explanations for this transient decrease
in hemoglobin: (1) continuing hemolysis from malaria before

parasitemia was cleared; (2) hemodilution as a result of adequate
hydration being restored during clinical support of the patient. In
corroboration of (1), we know it takes up to 48 hours to clear
parasitemia22; in support of (2), other analytes, such as unconjugated bilirubin, also decreased from day 1 to day 2 (Figure 2D).
None of the children required blood transfusion. Thus, we confirm
that there is no evidence of AHA with AL and in this respect, the
children who received AL can be regarded as a control group.
With respect to platelets, there was an unexplained greater
increase in platelet counts in heterozygotes than in G6PD-normal
or G6PD-deficient patients (Table 2). On the other hand, on
treatment of malaria, there was no statistically significant difference in platelets between G6PD-deficient and G6PD-normal patients (18.0 X 109/L; 95% confidence interval [95% CI] -35.1,
71.1; Table 2).
Clinical course in G6PD-deficient children receiving dapsone

Almost all of the G6PD-deficient children who received dapsone
showed evidence of hemolysis, with a marked decrease in hemoglobin (Figure 1, Figure 3). Whereas before treatment the erythrocyte
morphology often was normal, except for the presence of P falciparum (Figure 4A), morphologic changes in the erythrocytes
consistent with oxidative damage could be seen clearly in these
G6PD-deficient children from day 1 (approximately 24 hours after
the first dapsone dose), at a time when malaria parasites were still
visible (Figure 4B). By day 3, the morphologic evidence of
oxidative damage was prominent (Figure 4C).
In most G6PD-deficient children receiving dapsone, there was a
gradual recovery of hemoglobin, which returned to the original
level between days 28 and 42: this was heralded by a highly
significant increase in reticulocytes, peaking at day 7 (Figure 2B).
There was also a peak in WBC count at day 7 in hemizygous
G6PD-deficient boys (although not for homozygous G6PDdeficient girls; Figure 2C). A substantial fraction of hemolysis in
G6PD-deficient subjects exposed to an oxidative agent is extravascular27 and therefore reflected in hyperbilirubinemia (Figure 2D).
Statistical analysis of all of these findings is presented in Table 2.
Unfortunately, we do not have complete records of hemoglobinuria, a reliable index of intravascular hemolysis.
Given the large number (n = 119) of G6PD-deficient hemizygous boys and homozygous girls who received dapsone, we can chart
rather precisely the course of the hemolytic attack (Table 3). The average
lowest hemoglobin concentration across the observation period
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Dapsone, mean ± SE for:
G6PD-deficient hemizygous male
G6PD-deficient homozygous female
Heterozygous female
G6PD-normal female
G6PD-normal male
Control (artemether-lumefantrine), mean ± SE
All patients
2.0

1.5

1.0

Hemoglobin, g/dL (± SE)

0.5

0

–0.5

–1.0

N
95
24

–1.5

197
511

–2.0

623
360

–2.5
0

5

10

15

20

25

30

35

40

45

Study day
Figure 1. Change in hemoglobin concentrations relative to values obtained at day 1 in children receiving a dapsone-containing combination or AL for the treatment
of falciparum malaria. For changes from pretreatment (day 0) values, see supplemental Figure 1.

was 7.20 g/dL. The mean maximum decrease in hemoglobin versus
pretreatment values was -2.64 g/dL. Considering that the majority
of children were anemic before treatment, it is important also to
consider the decrease in hemoglobin as the percentage of the
pretreatment level; on average -26.0%. The mean maximum
decrease versus the day 1 value was -2.08 g/dL. All of these
parameters were significantly different from the AL group; statistical data are presented in Table 3.
In 13 of 119 (10.9%) G6PD-deficient children treated with
dapsone, the hemolytic attack was severe enough to require blood
transfusion, which was administered on days 4-7 (supplemental
Table 1 and illustrative clinical summaries). One heterozygous
female and 2 G6PD-normal male patients also required a blood
transfusion.
In 2 of the 95 G6PD-deficient hemizygous boys who received
dapsone, there was no decrease in hemoglobin. One was a
4-year-old boy who had received a recent blood transfusion for
“malarial anemia” and had a pretreatment hemoglobin level of
11.4 g/dL. It seems probable that the transfused (presumably
G6PD-normal) erythrocytes “masked” hemolysis of the boy’s
endogenous erythrocytes. The other was a 3-year-old hemizygous
boy who had a pretreatment hemoglobin level of 7.9 g/dL; in this
case, we can only speculate that the child, perhaps in response to
preexisting anemia, might have had a young erythrocyte population
that would be less sensitive to oxidative hemolysis.
In the girls heterozygous for G6PD deficiency treated with
dapsone (n = 200), the mean maximum decrease in hemoglobin

concentration was -1.83 ± 1.09 g/dL. The maximum decrease
in hemoglobin for heterozygotes was intermediate between that
of G6PD-normal and G6PD-deficient patients (Figure 5). Statistical analysis showed that the mean maximum decrease in
hemoglobin for heterozygotes was significantly less then that
observed for G6PD-deficient patients (adjusted difference
-0.91 g/dL; 95% CI -0.68, -1.14) but significantly greater
than for G6PD-normal patients (adjusted difference -4.3 95%
CI -2.7, -5.8; Table 2). However, in some of the heterozygotes, the hemolytic attack was as severe as in some of the
homozygous females (Figure 6).
Methemoglobinemia is known to occur with dapsone; indeed,
we found that in the children who received dapsone, the mean
highest posttreatment level was 5.2%, (n = 30) whereas in those
that received AL it was 1.9% (n = 10). Within the dapsone group,
the mean highest posttreatment methemoglobin level in G6PDdeficient children (n = 5) was 8.0% (range 3.2%-15.1%), compared with 4.5% (range 1.5%-15.3%) in G6PD-normal children
(n = 21; see supplemental Table 2 for individual patient data and
supplemental Figure 2B for data summary).

Discussion
Dapsone regularly causes hemolysis in G6PD-deficient children
with malaria. Morphologic changes in the erythrocytes of these
children were visible as early as 24 hours after the start of
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4.9 (-17.3, 27.0)
1.5 (-28.6, 31.5)
6.3 (-15.2, 27.9)
.273

.002

-5.7 (-23.2, 11.8)
-4.3 (-18.0, 9.4)
ALT, IU/L

13.7 (-3.9, 31.4)

2.1 (-13.4, 17.6)
-2.2 (-23.3, 18.8)
-0.2 (-15.3, 15.0)
.796

.028

-43.3 (-78.5, -8.1)
-27.4 (-55.0, 0.1)
Platelets X109/L

1.4 (-10.3, 13.1)

99.4 (44.9-153.8)
-81.3 (-155.2, -7.4)
18.0 (-35.1, 71.1)
.053

.129

-2.3 (-6.3, 1.8)
< .001
0.0 (-2.7, 2.8)
6.8 (2.8-10.7)
6.8 (3.8-9.8)

15.8 (-7.6, 39.2)

-5.3 (-9.5, -1.2)

.956

Unconj bil, f-Lmol/L

0.3 (-0.8, 1.4)
1.4 (0.6-2.3)
WBC X109/L

1.1 (0.4-1.8)

1.0 (-0.4, 2.5)

3.1 (-2.6, 8.7)

1.2 (-0.3, 2.7)

.400

< .001

-0.2 (-2.2, 1.9)

-0.1 (-0.9, 0.7)
0.2 (-1.0, 1.3)
0.1 (-0.8, 0.9)
< .001
1.4 (0.8-2.0)
1.0 (0.1-2.0)
2.4 (1.7-3.1)
Reticulocytes, %

.863
0.08 (0.44, -0.28)

-0.9 (0.4, -2.1)
0.7 (2.4, -1.1)

-0.02 (0.47, -0.51)
0.06 (0.41, -0.29)

-0.2 (1.1, -1.5)
< .001

< .001

-2.8 (-2.0, -3.5)
-3.8 (-3.2, -4.4)
Hematocrit, %

-1.0 (-0.5, -1.5)

-0.91 (-0.68, -1.14)
-1.34 (-1.15, -1.52)
Hemoglobin, g/dL

Heterozygous vs
G6PD normal
G6PD deficient vs
heterozygous
G6PD deficient vs
G6PD normal
Parameter

-0.43 (-0.27, -0.58)

Analysis of
variance P*
Heterozygous
vs G6PD normal

Artemether-lumefantrine

G6PD deficient
vs heterozygous
G6PD deficient
vs G6PD normal
Analysis of
variance P*

Dapsone

Table 2. Adjusted mean difference between G6PD genotypes in the maximum change from pretreatment values for clinically important laboratory parameters in malaria patients receiving
dapsone or AL
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therapy, and the consequent hemolysis resulted in a hemoglobin
nadir recorded at day 7, with eventual recovery in most children
by day 28.
Although from different parts of Africa, the 119 G6PD-deficient
boys and girls included in this analysis constitute a rather homogenous group because they all presented with acute P falciparum
malaria and received the same dose of dapsone (2.5 mg/kg/d given
for 3 days) within the CDA or the chlorproguanil-dapsone combination. In addition, they all had the same G6PD variant, A-. The
hemolysis was associated with hyperbilirubinemia, and it was
regularly followed by a significant reticulocyte response (Figure 2).
To the best of our knowledge, the time course of these hematologic
changes has never been previously reported for such a large series
of G6PD-deficient patients with drug-induced AHA. Leukocytosis—
with a predominance of granulocytes—may occur in favism,28 and
here we confirm that it also occurs in drug-induced AHA. Although
urinalysis was not performed routinely, dark urine was noted,
particularly in the children who required blood transfusion.
Dapsone-induced hemolysis had previously been studied experimentally in G6PD-deficient healthy adult male volunteers.21 Dapsone was given for 21 days to 5 G6PD-deficient subjects in doses
ranging from 25 to 200 mg/d (0.4-2.5 mg/kg/d) and to 10 G6PDnormal controls at doses of 50-300 mg/d (0.7-4.1 mg/kg/d).21 The
one G6PD-deficient subject who received a dose similar to that in
this series (200 mg/d, equivalent to about 2.5 mg/kg/d) had a
decrease in hemoglobin of approximately -3.6 g/dL (it was
expressed in the original article in terms of hematocrit). The other
drug causing AHA in G6PD-deficient subjects that has been studied
experimentally is primaquine: in 6 primaquine-sensitive (subsequently proven to be G6PD-deficient) adult volunteers, 30 mg/d for
6 days (approximately 0.4 mg/kg/d) caused a decrease in hemoglobin of approximately -4.0 g/dL.12 This was evident on day 2 to day
3 (often associated with passing dark urine), reached a nadir about
day 8, followed by recovery to pretreatment hemoglobin levels by
about day 28, without blood transfusion.12,29,30 The authors remarked that in the only subject who took part in both studies, the
hemolysis caused by dapsone 100 mg/d was somewhat less than
that caused by primaquine 30 mg/d.21
Several factors can influence the severity of a drug-induced
hemolytic attack in a G6PD-deficient subject, including the pharmacology of the drug, the dose, the G6PD mutation, the age, and
coexisting disease conditions. If we take into account the differences between the current report and the volunteer studies,
particularly with respect to age, the findings are remarkably similar.
This is possibly because the volunteer subjects were all AfricanAmerican, and it became known subsequently that the most
common G6PD mutation in African-Americans is G202A, A376G
(V68M, N126D),31 the same mutation found in the children in this
study.24 On the other hand, there were 2 differences. First, in the
volunteer studies, drug sensitivity decreased with continued drug
challenge because of a gradual increase in the proportion of young
erythrocytes, which have greater G6PD activity than aging cells.30
This did not take place in the current study because dapsone was
given for only 3 days. The other, more important difference is that
the serious hemolytic effect of dapsone was made more dangerous
and sometimes life-threatening in these children because they
had malaria, and particularly malarial anemia; at study start 93 of
119 (78.2%) of the hemizygous G6PD-deficient children were
anemic, and 7 of 119 (5.9%) were severely anemic (according to
WHO definitions).32 In addition, the same absolute decrease in
hemoglobin in a child must be regarded as more “severe” than a
similar decrease in an adult male because normal hemoglobin
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Dapsone, mean ± SE for:
G6PD-deficient hemizygous male
G6PD-deficient homozygous female
Heterozygous female
G6PD-normal female
G6PD-normal male
Control (artemether-lumefantrine), mean ± SE

36

14

34

13

White blood cell count,
x109/L (± SE)

Hematocrit, % (± SE)

All patients

32
30
28
26

N
95
24
200
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630
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11
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9
8
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6
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Figure 2. Hemolytic anemia in G6PD-deficient children with malaria receiving therapy with a dapsone-containing combination. The 4 panels report the following
clinically important parameters: (A) hematocrit; (B) reticulocytes; (C) white blood cell count; and (D) unconjugated bilirubin. In each panel, the shaded area reflects data from
the control group (children receiving AL), and the line plots represent mean values ± SE for children receiving a dapsone-containing combination for the 2 male and the
3 female G6PD genotypes. Similar panels for other laboratory parameters are in supplemental Figures 1 and 2.

levels are lower in children younger 12 years of age (11.5 g/dL)
than in adult men (13.0 g/dL).32
Variable severity of hemolysis

Of 119 G6PD-deficient children, 26 (21.8%) had a decrease in
hemoglobin of only 13% or less (the mean change in the AL
group) versus pretreatment. At the other end of the scale, 24 of
119 (20.2%) G6PD-deficient children had a hemoglobin decrease
> 40% versus pretreatment. Such a great variation may appear at
first surprising. We did not measure G6PD enzyme activity in this
study, but it is possible that in some patients, previous anemia
associated with either malnutrition or malaria or both could
generate a young erythrocyte population relatively resistant to the
oxidative effect of dapsone. The intensity, duration, and variable
combination of such factors could account for variability in the
hemolytic response to dapsone. In addition, we know very little
about the interactions of G6PD with other genetic traits that may
affect the vulnerability of erythrocytes with respect to oxidative
challenge.
Mechanism of action of dapsone

The most extensive use of dapsone has been in the long-term
therapy of leprosy. In several studies, a decrease in the mean
hemoglobin level of the order of between -1.0 g/dL and -2.0 g/dL

has been documented; and in different studies from 5% to 25% of
patients, not all of them G6PD deficient, have developed overt
hemolytic anemia.33-35 Apparently, the oxidative action of dapsone
is so potent that it can cause damage even to G6PD-normal
erythrocytes, but it stands to reason that the damage will be far
more severe when the erythrocytes are G6PD deficient. In the
current study, there was no evidence of dapsone-related hemolysis
in G6PD-normal children, possibly because of the short duration of
dapsone therapy used to treat malaria.
Although the precise mechanisms whereby dapsone (4,4'diaminodiphenylsulfone, or DDS) causes methemoglobinemia and
hemolysis are not fully elucidated, several points about its metabolism have been established (see supplemental Figure 3). First, the
active molecule, DDS, can be inactivated by acetylation to
monoacetyl dapsone; and the steady-state balance between DDS
and monoacetyl dapsone can be influenced by genetic polymorphism of N-acetyltransferase-2. DDS is also converted to a
hydroxylamine derivative (DDS-NHOH) by enzymes of the P450
cytochrome family; DDS-NHOH is the main metabolite thought to
be responsible for the hematologic toxicity of dapsone.36,37 This
toxicity depends in part on a reaction between DDS-NHOH and
hemoglobin that, in the presence of oxygen, produces methemoglobin and nitroso-dapsone.36 Reactive oxygen radicals (ROS) are
known to be generated whenever hemoglobin is converted to
methemoglobin, perhaps in greater amounts in the presence of
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Figure 3. Variability in hemoglobin levels in individual patients. (A) G6PDdeficient hemizygous male patients (n = 95); (B) G6PD-deficient homozygous
female patients (n = 24).

DDS-NHOH and nitroso-dapsone.36 ROS are normally detoxified
by GSH, the supply of which ultimately depends on G6PD (see
supplemental Figure 3). Consistent with this, in liver microsomes
GSH and NADPH are protective against dapsone-induced cellular
damage, precisely the molecules that are in limited supply in
G6PD-deficient erythrocytes.37 Thus, we can visualize how methemoglobinemia follows dapsone administration independent of
G6PD status (as we have indeed observed), whereas the threat
posed by ROS to erythrocytes is much greater if these are deficient
in G6PD.
Recent work has shown that DDS-NHOH can produce changes
in erythrocyte membrane proteins,38 specifically affecting the
phosphorylation of band 3. This can cause hemolysis even in
G6PD-normal individuals.33-35 However, in G6PD-deficient erythrocytes, membrane remodeling appears to be increased.38 Presumably membrane damage combined with the pressure from ROS
ultimately causes the demise of G6PD-deficient cells. Coming back
to our patients, serial blood smears have enabled us to visualize
dapsone in action: on one hand, the malaria parasites are being
dramatically affected—as expected—in number and in shape
(Figure 4A-B), and at the same time the erythrocytes are experiencing severe oxidative damage (Figure 4B-C). It is probably the first
time that this has been documented.
Hemolysis in G6PD heterozygotes

Data on drug-induced AHA in females heterozygous for G6PD
deficiency are limited to case reports. This series included 200 girls
who were heterozygous for G6PD A-. From the individual trials, it

Figure 4. Blood smears from a 3-year-old boy with acute malaria and G6PD
deficiency treated with chlorproguanil-dapsone. (A) Pretreatment: black arrows
point to erythrocytes parasitized by P falciparum (ring forms), the white arrow points
to an erythrocyte containing 2 rings of P falciparum. (B) Approximately 24 hours after
starting treatment (day 1): on the left abnormally shaped parasites are seen within
spherocytes, on the right a parasite in a severely contracted erythrocyte. (C) On day
3: numerous contracted erythrocytes, spherocytes, and hemighosts (often referred to
as “bite cells”; arrows). Inset: another hemighost at a greater magnification; the part of
the erythrocyte that appears to be missing is the negative image of a Heinz body.51
Slides were prepared with Giemsa stain and Zeiss immersion oil. An Orthoplan light
microscope was used (Leitz). Panel C (except the inset) was taken with an objective
Plan-Apochromatic X63 oil, aperture number 1.4 (Zeiss). The inset to panel C and all
other photos were taken with objective X100 oil, aperture number 1.3 (Leitz). Imaging
was with a ProgRes C10plus (Jenoptik-Laser Optik Systeme) with acquisition
software ProgRes Capture Basic (Jenoptik) running under Windows XP on a
personal computer (assembled).
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Table 3. Changes in clinically important hematologic and clinical chemistry parameters in G6PD-deficient malaria patients after receiving
dapsone
Laboratory parameter

Dapsone G6PD deficient
(n = 119)*

Control group
(n = 366)

Adjusted difference
(95% CI)†

Hemoglobin
7.20 ± 1.50

8.64 ± 1.41

Maximum decrease from pretreatment, g/dL

-2.64 ± 1.58

-1.37 ± 1.06

-1.46 (-1.76, -1.15)

Maximum decrease from pretreatment, %

-26.0 ± 13.9

-13.2 ± 9.9

-13.9 (-16.8, -11.0)

Maximum decrease from day 1 value, g/dL

-2.08 ± 0.46

-0.56 ± 1.47

7.50 ± 1.57

9.76 ± 1.48

Highest value

6.4 ± 6.6

2.3 ± 2.5

1.4 (0.5-2.3)

Maximum increase from pretreatment

4.9 ± 6.3

1.2 ± 2.3

1.4 (0.5-2.3)

13.9 ± 5.9

11.8 ± 4.5

2.3 (1.1-3.5)

4.0 ± 5.8

2.9 ± 4.1

1.7 (0.5-2.9)

12.9 ± 14.3

4.1 ± 5.5

5.0 (2.3-7.8)

4.4 ± 13.7

-1.1 ± 7.3

4.4 (1.0-7.9)

Lowest value, g/dL

Day 7 value, g/dL

-1.04 (-1.29, -0.79)

-1.61 (-1.91, -1.30)
-1.80 (-2.08, -1.51)

Reticulocytes, %

White blood count, x109/L
Highest value
Maximum increase from pretreatment
Unconjugated bilirubin, f.1mol/L
Highest value
Maximum increase from pretreatment

Values are mean ± SD except where indicated otherwise. The control group received artemether-lumefantrine. Changes from pretreatment were defined as maximum
decrease (or minimum increase) for hemoglobin and hematocrit and as maximum increase (or minimum decrease) for other parameters.
*Total of 95 G6PD-deficient hemizygous male plus 24 G6PD-deficient homozygous female patients.
†Difference between treatment groups adjusted for sex, center, age, weight, pretreatment hemoglobin, and G6PD status. For dapsone subjects, a term was also fitted for
study (trial 005 or 006).

appeared that female heterozygotes were at no greater risk of
clinically significant hemolysis than G6PD normal patients.22,23
However, the greater power of the current pooled analysis has
allowed us to outline the spectrum of severity of hemolysis in
heterozygotes. As expected, overall this is significantly less than
in G6PD-deficient children and is highly variable (Table 2,
Figure 5) as can be expected from erythrocyte mosaicism.
Indeed, as a result of random X-chromosome inactivation in
G6PD heterozygotes, on average 50% of erythrocytes will be
G6PD deficient, but the scatter around this mean is wide.39,40
One would expect, therefore, that the severity of hemolysis in
heterozygotes will be, on average, approximately half that
observed for hemizygous G6PD-deficient males. This is indeed
the case with respect to favism41; and it has been assumed, but
had been never previously proven, for drug-induced AHA. Here
for the first time it has become possible to test this theoretical
prediction. We found that indeed the decrease in hemoglobin in
this group was approximately half way between that of G6PDnormal and that of G6PD-deficient children (Figure 5). At the
same time, not surprisingly, within the heterozygote group there
were individual cases with severe hemolysis or hardly any
hemolysis (Figure 6).

Hemolysis and AL

We found no evidence of G6PD-related hemolysis with AL. A
mild decrease in hemoglobin from day 0 to day 1 was reversed
in the first few days of therapy across all G6PD genotypes. The
mechanism of action of artemisinins is thought to involve the
alkylation of heme digested by P falciparum,42 although artemisinin activation also can be triggered by undigested hemoglobin. 43 There are a few cases in the literature of hemolytic anemia
during or after treatment with intravenous artesunate alone or in
combination with mefloquine, and one report after oral treatment with AL in a (G6PD normal) patient with HIV and severe
falciparum malaria.44 However, these are rare adverse events. It
appears that clinically, in the majority of patients administered
artemisinins, the presence of malaria and dehydration rather
than the drug exert the most important effects on hematologic
parameters.
Testing for G6PD deficiency

It is fortunate that there are today effective antimalarials that can be
used safely for the treatment of P falciparum infection in G6PDdeficient children. However, if one had to use a potentially

100

Cumulative frequency, %
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G6PD-deficient males and females (N = 119)
Heterozygous females (N = 200)
G6PD-normal males and females (N = 1145)
Control (artemether-lumefantrine)
All patients (N = 366)
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Figure 5. The G6PD genotype was a major determinant of the severity of anemia in children given dapsone. The cumulative frequency of the maximum decrease in
hemoglobin concentration versus pretreatment levels in G6PD-normal children given dapsone was similar to that of the control group; in G6PD-deficient children it is much
greater, and in girls heterozygous for G6PD deficiency it is intermediate.
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Figure 6. Illustrative examples of the hematologic
impact of dapsone in individual patients with falciparum malaria. These 4 girls were all from the same site
(Ouagadougou, Burkina Faso). (A) was G6PD normal,
(B) was homozygous for G6PD deficiency, and (C) and
(D) were heterozygous for G6PD deficiency. It is seen
that one of the heterozygotes behaved almost exactly like
a G6PD-normal child, whereas the other behaved almost
exactly like a homozygous G6PD-deficient child.
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hemolytic agent, as is the case for primaquine with respect to
Plasmodium vivax eradication, then testing for G6PD deficiency
would be imperative. Although in the past this has been regarded as
an unrealistic proposition for many malaria-endemic areas, testing
is now possible with minimal facilities (rapid diagnosis test) at low
cost and results can be available within an hour.45 A reservation
raised commonly with respect to G6PD tests is that they would fail
to detect a fraction of heterozygotes. This is certainly true, but those
heterozygotes that risk being misclassified as G6PD normal are
those that have a majority of G6PD-normal erythrocytes, and
therefore they are unlikely to develop a serious hemolytic attack.
Severe hemolytic anemia in G6PD A-

Since the 1960s, a widespread notion about the risk of AHA in
G6PD deficiency has been that its severity depends on the specific
G6PD variant involved.46 This was based largely on the observation that when primaquine was administered experimentally to
G6PD-deficient subjects from Sardinia (who presumably had the
G6PD Mediterranean mutation),47 it caused a more severe hemolytic attack than previously reported in African-Americans with
G6PD A-.30 In addition, the mean value of G6PD activity in
erythrocytes with G6PD Med is lower than in erythrocytes with
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Time (days)

20

25

30

G6PD A-. A statement in the report of a WHO meeting held in
1966 led to the term “mild” being used for G6PD A-.46 This
document also stated that favism, a severe clinical manifestation
of G6PD deficiency, did not occur in G6PD A- individuals. 46
However, it became clear subsequently that this statement was
incorrect: subjects with G6PD A- can develop severe favism.48-50
Despite numerous case reports of severe hemolysis occurring
after oxidative challenge in patients with G6PD A-, the notion
that the clinical implications of G6PD A- are generally mild
has persisted. It is evident from this analysis that patients with
G6PD A- are at risk of a serious hemolytic attack whenever the
trigger is powerful enough. It remains of course possible that
with the same dose of dapsone that was used in these children,
hemolytic attacks might be even more severe with other G6PD
variants. In the meantime, we submit that the term “mild” for the
G6PD A- type of G6PD deficiency can be misleading and
should best be abandoned.
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